Diabetes Mellitus, a syndrome of disordered metabolism, characterised by abnormal elevation in blood glucose level, has become a life-threatening condition for many people. Current means of therapy for Diabetes Mellitus do not mimic the normal physiological pattern of insulin release. Oral delivery is the preferred route of administration due to its non-invasive nature. Oral delivery of insulin presents an overview of Diabetes Mellitus, and discusses the strategies and techniques adopted for oral delivery of insulin. This title begins with an introductory chapter on symptoms, complications and therapy for Diabetes Mellitus. Subsequent chapters cover the various routes for administering insulin; the challenges and strategies of oral delivery; experimental techniques in the development of an oral insulin carrier; lipids; inorganic nanoparticles and polymers in oral insulin delivery; and a summary and presentation of future perspectives on oral delivery of insulin. Presents an overview of Diabetes Mellitus Includes a discussion of various strategies and techniques adopted for oral delivery of insulin Presents an update of research in the field

Parenteral administration remains the mainstay of drug administration for protein therapeutics. However, for diseases that require frequent drug dose over long periods of time, injections can result in patient incompliance and poor treatment outcomes. For such diseases, oral drug delivery is the most non-invasive and patient-compliant method of drug administration. Although oral delivery of many small molecule drugs is routine, oral delivery of protein drugs - e.g. insulin presents several challenges including oral bioavailability of the protein therapeutic because of degradation in the stomach, inactivation and digestion of the therapeutics by the proteolytic enzymes in the luminal cavity, and poor permeability of drugs across the intestinal epithelium. Polymeric nanoparticle (NP) carriers provide new opportunities for controlled delivery of drugs, and have the potential to address challenges associated with effective oral delivery of insulin. NPs can protect the protein therapeutic from degradation in the GI tract as well as allow targeted transport across the epithelial lining. An efficient NP based oral insulin delivery solution that can enable targeted transport of insulin across the GI tract must have (1) high insulin loading, (2) sub-100 nm size, (3) ability to release insulin before opsonization by macrophages and (4) the ability to be surface-functionalized with ligands that facilitate transport across the epithelium. This work presents a detailed study on mechanistic understanding of polymeric insulin NP formation with a focus on the effect of synthesis parameters on insulin loading and NP size. We report how buffer conditions, ionic chelation, and NP preparation methods influence insulin loading in poly (lactic-co-glycolic acid)-b-poly(ethylene glycol) (PLGA-PEG) NPs. We report a 10-fold increase in insulin loading with the use of chelating zinc ions and by the optimization of the pH during nanoprecipitation. Next, we report the development of novel insulin Eudragit-PLGA-PEG blended NPs (Ins-Eud-NPs) with high insulin loading (13.1%) and sub-100 nm size. These NPs enable rapid release of insulin when triggered by a change in pH that occurs when the NPs cross the duodenal epithelium and go from acidic to neutral pH. The NPs are formed by successfully blending Eudragit S100, a commercially available polymer which dissolves at pH greater than 7 with a non-pH responsive polymer, PLGA-PEG. To enable effective transport of these NPs across the epithelial lining, NPs were designed to use the FcRn transport pathway that mediates IgG antibody transport across epithelial barriers. We report the successful chemical conjugation of the Fc fragment on the surface of Ins-Eud- NPs by overcoming the presence of non-ideal conjugation parameters owing to the pH restrictions of the system. This dissertation provides mechanistic insights and helps to understand fundamental concepts about polymeric NP formation and protein encapsulation. The modular NP system developed in this work can be extended to other protein drug delivery systems that are subject to limited drug loading and restricted transport across epithelial barriers.

In recent years, the fabrication of nanomaterials and exploration of their properties have attracted the attention of various scientific disciplines such as biology, physics, chemistry, and engineering. Although nanoparticulate systems are of significant interest in various scientific and technological areas, there is little known about the safety of these nanoscale objects. It has now been established that the surfaces of nanoparticles are immediately covered by biomolecules (e.g. proteins, ions, and enzymes) upon their entrance into a biological medium. This interaction with the biological medium modulates the surface of the nanoparticles, conferring a “biological identity” to their surfaces (referred to as a “corona”), which determines the subsequent cellular/tissue responses. The new interface between the nanoparticles and the biological medium/proteins, called “bio-nano interface,” has been very rarely studied in detail to date, though the interest in this topic is rapidly growing. In this book, the importance of the physiochemical characteristics of nanoparticles for the properties of the protein corona is discussed in detail, followed by comprehensive descriptions of the methods for assessing the protein-nanoparticle interactions. The advantages and limitations of available corona evaluation methods (e.g. spectroscopy methods, mass spectrometry, nuclear magnetic resonance, electron microscopy, X-ray crystallography, and differential centrifugal sedimentation) are examined in detail, followed by a discussion of the possibilities for enhancing the current methods and a call for new techniques. Moreover, the advantages and disadvantages of protein-nanoparticle interaction phenomena are explored and discussed, with a focus on the biological impacts.

Biopharmaceutical medicines, the newest class of therapeutics, are quite heterogeneous and include a range of molecules such as proteins, peptides, vaccines and nucleic acids, with use in virtually all therapeutic fields (e.g. cancer and infectious diseases, vaccination, metabolic dysfunctions) and diagnostics. This edited book gives a concise and up-to-date overview of the biological features justifying the use of different human mucosa as delivery routes for biopharmaceuticals, the technological strategies that have been followed so far regarding the optimization of mucosal potentialities as well as the challenges that arise with the advent of new biopharmaceutical drugs and alternative means of administration. Following a brief introduction, the first section addresses general aspects of the biology of mucosal tissues and their unique aspects toward beneficial or deleterious interaction with biopharmaceuticals and their delivery systems. The second part reviews the different delivery strategies that have recently been investigated for different mucosal sites. The third section describes the development and clinical applications of drug delivery systems and products enclosing biopharmaceuticals for mucosal delivery, with a focus on the most successful case studies of recent years. The last section briefly centers on relevant aspects of the regulatory, toxicological and market issues of mucosal delivery of biopharmaceuticals.​ Scientists and researchers in the fields of drug delivery, material science, biomedical science and bioengineering as well as professionals, regulators and policy makers in the pharmaceutical, biotechnology and healthcare industries will find in this book an important compendium of fundamental concepts and practical tools for their daily research and activities.